

DAFTAR PUSTAKA

- Archer, S. L., Marsboom, G., Kim, G. H., Zhang, H. J., Toth, P. T., *et al.* (2010). Epigenetic Attenuation of Mitochondrial Superoxide Dismutase 2 in Pulmonary Arterial Hypertension: A Basis for Excessive Cell Proliferation and a New Therapeutic Target. *Circulation*, *121*(24), 2661–2671. <https://doi.org/10.1161/CIRCULATIONAHA.109.916098>
- Arthur, H. M., & Bamforth, S. D. (2011). TGF β Signaling and Congenital Heart Disease: Insights from Mouse Studies. *Birth Defects Research Part A - Clinical and Molecular Teratology*, *91*, 423–434. <https://doi.org/10.1002/bdra.20794>
- Babiarz, J. E., Ruby, J. G., Wang, Y., Bartel, D. P., & Blelloch, R. (2008). Mouse ES Cells Express Endogenous shRNAs, siRNAs, and Other Microprocessor-independent, Dicer-dependent Small RNAs. *Genes and Development*, *22*(20), 2773–2785. <https://doi.org/10.1101/gad.1705308>
- Balzano, F., Deiana, M., Giudici, S. D., Oggiano, A., Baralla, A., *et al.* (2015). miRNA Stability in Frozen Plasma Samples. *Molecules*, *20*, 19030–19040. <https://doi.org/10.3390/molecules201019030>
- Barst, R. J., Ivy, D. D., Foreman, A. J., Mcgoon, M. D., & Rosenzweig, E. B. (2014). Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease e Associated Pulmonary Arterial Hypertension (from the REVEAL Registry). *The American Journal of Cardiology*, *113*(1), 147–155. <https://doi.org/10.1016/j.amjcard.2013.09.032>
- Barst, R. J., McGoon, M. D., Elliott, C. G., Foreman, A. J., Miller, D. P., *et al.* (2012). Survival in Childhood Pulmonary Arterial Hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management. *Circulation*, *125*(1), 113–122. <https://doi.org/10.1161/CIRCULATIONAHA.111.026591>
- Bauersachs, J., & Thum, T. (2011). Biogenesis and regulation of cardiovascular microRNAs. *Circ Res*, *109*, 334–347.
- Bentley, R. F., Barker, M., Esfandiari, S., Wright, S. P., Valle, F. H., *et al.* (2020).

- Normal and Abnormal Relationships of Pulmonary Artery to Wedge Pressure During Exercise. *Journal of the American Heart Association*, 9, 1–12. <https://doi.org/10.1161/JAHA.120.016339>
- Boucly, A., Weatherald, J., Savale, L., Groote, P. De, Cottin, V., *et al.* (2022). External Validation of a Refined Four-Stratum Risk Assessment Score from the French Pulmonary Hypertension Registry. *European Respiratory Journal*, 59, 1–12. <https://doi.org/10.1183/13993003.02419-2021>
- Boucly, A., Weatherald, J., Savale, L., Jaïs, X., Cottin, V., *et al.* (2017). Risk Assessment, Prognosis and Guideline Implementation in Pulmonary Arterial Hypertension. *European Respiratory Journal*, 50(2), 1–10. <https://doi.org/10.1183/13993003.00889-2017>
- Brock, M., Haider, T. J., Vogel, J., Gassmann, M., Speich, R., *et al.* (2015). The Hypoxia-induced microRNA-130a Controls Pulmonary Smooth Muscle Cell Proliferation by Directly Targeting CDKN1A. *International Journal of Biochemistry and Cell Biology*, 1–9. <https://doi.org/10.1016/j.biocel.2015.02.002>
- Budhiraja, R., Tuder, R. M., & Hassoun, P. M. (2004). Endothelial Dysfunction in Pulmonary Hypertension. *Circulation*, 109(2), 159–165. <https://doi.org/10.1161/01.CIR.0000102381.57477.50>
- Çakmak, H. A., & Demir, M. (2020). MicroRNA and Cardiovascular Diseases. *Balkan Medical Journal*, 37(2), 60–71. <https://doi.org/10.4274/balkanmedj.galenos.2020.2020.1.94>
- Chen, D., Zhang, Z., & Meng, Y. (2015). Systematic tracking of disrupted modules identifies altered pathways associated with congenital heart defects in down syndrome. *Medical Science Monitor*, 21, 3334–3342. <https://doi.org/10.12659/MSM.896001>
- Chen, W., & Li, S. (2016). Circulating microRNA as a Novel Biomarker for Pulmonary Arterial Hypertension Due to Congenital Heart Disease. *Pediatr Cardiol*, 1–9. <https://doi.org/10.1007/s00246-016-1487-3>
- Chen, Y., & Gorski, D. H. (2008). Regulation of Angiogenesis Through a microRNA (miR-130a) that Down-regulates Antiangiogenic Homeobox

- Genes GAX and HOXA5. *Blood*, *111*(3), 1217–1226.
<https://doi.org/10.1182/blood-2007-07-104133>
- Cheng, Y., Wang, D., Wang, F., Liu, J., Huang, B., *et al.* (2020). Endogenous miR-204 Protects the Kidney against Chronic Injury in Hypertension and Diabetes. *JASN*, *31*, 1539–1554.
- Chiu, S. N., Lu, C. W., Lin, M. T., Chen, C. A., Wu, M. H., *et al.* (2022). Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease. *J Am Heart Assoc*, *11*, 1–11.
<https://doi.org/10.1161/JAHA.121.022596>
- Chowdhury, S., Hobbs, C. A., Erickson, S. W., Macleod, S. L., Cleves, M. A., *et al.* (2011). Maternal Genome-Wide DNA Methylation Patterns and Congenital Heart Defects. *Plos One*, 1–13.
- Çiftel, M., Şimşek, A., Turan, Ö., Kardelen, F., Akçurin, G., *et al.* (2012). Endothelial Dysfunction and Atherosclerosis in Children with Irreversible Pulmonary Hypertension due to Congenital Heart Disease. *Annals of Pediatric Cardiology*, *5*(2), 160–164. <https://doi.org/10.4103/0974-2069.99619>
- Cui, R. R., Li, S. J., Liu, L. J., Yi, L., Liang, Q. H., *et al.* (2012). MicroRNA-204 Regulates Vascular Smooth Muscle Cell Calcification in vitro and in vivo. *Cardiovascular Research*, *96*, 320–329. <https://doi.org/10.1093/cvr/cvs258>
- Dhahri, W., Dussault, S., Légaré, É., Rivard, F., Desjarlais, M., *et al.* (2020). Reduced Expression of microRNA-130a Promotes Endothelial Cell Senescence and Age-Dependent Impairment of Neovascularization. *Aging*, *12*(11), 10180–10193.
- Dhillon, A. S., Hagan, S., Rath, O., & W Kolch. (2007). MAP Kinase Signalling Pathways in Cancer. *Oncogene*, *26*, 3279–3290.
- Diehl, P., Fricke, A., Sander, L., Stamm, J., Bassler, N., *et al.* (2012). Microparticles: major transport vehicles for distinct microRNAs in circulation. *Cardiovasc Res*, *93*, 633–644.
- Dinarti, L. K., Anggrahini, D. W., Lilyasari, O., Siswanto, B. B., & Hartopo, A. B. (2021). Pulmonary Arterial Hypertension in Indonesia : Current Status and Local Application of International Guidelines. *Global Heart*, *16*(1), 1–11.

- Dinarti, L. K., Hartopo, A. B., Kusuma, A. D., Satwiko, M. G., Hadwiono, M. R., *et al.* (2020). The COngenital HeARt Disease in Adult and Pulmonary Hypertension (COHARD-PH) registry: A Descriptive Study from Single-Center Hospital Registry of Adult Congenital Heart Disease and Pulmonary Hypertension in Indonesia. *BMC Cardiovascular Disorders*, 20(1), 1–11. <https://doi.org/10.1186/s12872-020-01434-z>
- Duffels, M. G. J., Engelfriet, P. M., Berger, R. M. F., Loon, R. L. E. Van, & Hoendermis, E. (2007). Pulmonary Arterial Hypertension in Congenital Heart Disease: An Epidemiologic Perspective from a Dutch Registry. *International Journal of Cardiology*, 120, 198–204. <https://doi.org/10.1016/j.ijcard.2006.09.017>
- Engelfriet, P. M., Duffels, M. G. J., Möller, T., Boersma, E., Tijssen, J. G. P., *et al.* (2007). Pulmonary Arterial Hypertension in Adults Born with a Heart Septal Defect: The Euro Heart Survey on Adult Congenital Heart Disease. *Heart*, 93(6), 682–687. <https://doi.org/10.1136/hrt.2006.098848>
- Engelfriet, P., & Mulder, B. J. M. (2009). Gender Differences in Adult Congenital Heart Disease. *Netherlands Heart Journal*, 17(11), 414–417. <https://doi.org/10.1007/BF03086294>
- Falcetti, E., Hall, S. M., Phillips, P. G., Patel, J., Morrell, N. W., *et al.* (2010). Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, (182), 1161–1170. <https://doi.org/10.1164/rccm.201001-0011OC>
- Fathala, A., & Aldurabi, A. (2021). Frequency of Computed Tomography Abnormalities in Patients with Chronic Thromboembolic Pulmonary Hypertension: a Comparative Study between Lung Perfusion Scan and Computed Tomography Pulmonary Angiography. *Multidisciplinary Respiratory Medicine*, 16(753), 1–6.
- Feng, Y., Zhou, S., Li, G., Hu, C., Zou, W., *et al.* (2016). Nuclear Factor- κ B-dependent microRNA-130a Upregulation Promotes Cervical Cancer Cell Growth by Targeting Phosphatase and Tensin Homolog. *Archives of*

- Biochemistry and Biophysics*, 1–23. <https://doi.org/10.1016/j.abb.2016.03.019>
- Frost, A., Badesch, D., Gibbs, J. S., Gopalan, D., Khanna, D., *et al.* (2019). Diagnosis of Pulmonary Hypertension. *European Respiratory Journal*, 53(1), 1–12. <https://doi.org/10.1183/13993003.01904-2018>
- Fu, Q., Lu, Z., Fu, X., Ma, S., & Lu, X. (2019). MicroRNA 27b Promotes Cardiac Fibrosis by Targeting the FBW7 / Snail Pathway. *Aging*, 11(24), 11865–11879.
- Galiè, N., Humbert, M., Vachiery, J. L., Gibbs, S., Lang, I., *et al.* (2016). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal*, 37(1), 67–119. <https://doi.org/10.1093/eurheartj/ehv317>
- Gilsbach, R., Preissl, S., Schnick, T., Burger, L., Benes, V., *et al.* (2014). Dynamic DNA Methylation Orchestrates Cardiomyocyte Development, Maturation and Disease. *Nature Communications*, 1–13. <https://doi.org/10.1038/ncomms6288>
- Glinge, C., Clauss, S., Boddum, K., Jabbari, R., Jabbari, J., *et al.* (2017). Stability of Circulating Blood-Based MicroRNAs – Pre-Analytic Methodological Considerations. *Plos One*, 1–16. <https://doi.org/10.1371/journal.pone.0167969>
- Grant, J. S., White, K., MacLean, M. R., & Baker, A. H. (2013). MicroRNAs in Pulmonary Arterial Remodeling. *Cell Mol Life Sci*, 70(23), 4479–4494. <https://doi.org/10.1007/s00018-013-1382-5>
- Grymuza, M., Malaczynska-Rajpold, K., Jankiewicz, S., Siniawski, A., Grygier, M., *et al.* (2017). Right Heart Catheterization Procedures in Patients with Suspicion of Pulmonary Hypertension – Experiences of a Tertiary Center. *Advances in Interventional Cardiology*, 13(4), 295–301. <https://doi.org/10.5114/aic.2017.71610>
- Guignabert, C., Tu, L., Hiress, M. Le, Ricard, N., Sattler, C., *et al.* (2013). Pathogenesis of Pulmonary Arterial Hypertension : Lessons from Cancer. *Eur Respir Rev*, 22, 543–551. <https://doi.org/10.1183/09059180.00007513>
- Gulyaeva, L. F., & Kushlinskiy, N. E. (2016). Regulatory Mechanisms of microRNA Expression. *Journal of Translational Medicine*, 1–10.

<https://doi.org/10.1186/s12967-016-0893-x>

- Halu, A., Liu, S., Baek, S. H., Hobbs, B. D., Hunninghake, G. M., *et al.* (2019). Exploring the Cross-Phenotype Network Region of Disease Modules Reveals Concordant and Discordant Pathways between Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. *Human Molecular Genetics*, 28(14), 2352–2364. <https://doi.org/10.1093/hmg/ddz069>
- Han, S., Wang, W. J., Duan, L., Hou, Z. L., Zeng, J. Y., *et al.* (2019). MicroRNA Profiling of Patients with Sporadic Atrial Septal Defect. *Biotechnology & Biotechnological Equipment*, 1–10. <https://doi.org/10.1080/13102818.2019.1591932>
- Harbaum, L., Fuge, J., Kamp, J. C., Hennigs, J. K., Simon, M., *et al.* (2020). Blood Carbon Dioxide Tension and Risk in Pulmonary Arterial Hypertension. *International Journal of Cardiology*, 318, 131–137. <https://doi.org/10.1016/j.ijcard.2020.06.069>
- Hautefort, A., Chesné, J., Preussner, J., Pullamsetti, S. S., Looso, M., *et al.* (2017). Pulmonary Endothelial Cell DNA Methylation Signature in Pulmonary Arterial Hypertension. *Oncotarget*, 8(32), 52995–53016.
- Hayden, L. P., Cho, M. H., McDonald, M. L. N., Crapo, J. D., Beaty, T. H., *et al.* (2017). Susceptibility to Childhood Pneumonia: A Genome-Wide Analysis. *American Journal of Respiratory Cell and Molecular Biology*, 56(1), 20–28. <https://doi.org/10.1165/rcmb.2016-0101OC>
- Hayder, H., O'Brien, J., Nadeem, U., & Peng, C. (2018). MicroRNAs: Crucial Regulators of Placental Development. *Reproduction*, 155(6), R259–R271. <https://doi.org/10.1530/REP-17-0603>
- He, L., & Hannon, G. J. (2004). MicroRNAs: Small RNAs with a Big Role in Gene Regulation. *Nature Reviews Genetics*, 5(7), 522–531. <https://doi.org/10.1038/nrg1379>
- He, S., Zhu, T., & Fang, Z. (2020). The Role and Regulation of Pulmonary Artery Smooth Muscle Cells in Pulmonary Hypertension. *International Journal of Hypertension*, 2020, 1–10.

- Hewes, J. L., Lee, J. Y., Fagan, K. A., & Bauer, N. N. (2020). The Changing Face of Pulmonary Hypertension Diagnosis: A Historical Perspective on the Influence of Diagnostics and Biomarkers. *Pulmonary Circulation*, *10*(1), 1–26. <https://doi.org/10.1177/2045894019892801>
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., *et al.* (2017). Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. *European Respiratory Journal*, *50*(2), 1–10. <https://doi.org/10.1183/13993003.00740-2017>
- Huang, J. B., Liang, J., Zhao, X. F., Wu, W. S., & Zhang, F. (2013). Epigenetics: Novel mechanism of pulmonary hypertension. *Lung*, *191*(6), 601–610. <https://doi.org/10.1007/s00408-013-9505-1>
- Huang, J., Zhao, L., Xing, L., & Chen, D. (2010). MicroRNA-204 Regulates Runx2 Protein Expression and Mesenchymal Progenitor Cell Differentiation. *Stem Cells*, *28*, 357–364. <https://doi.org/10.1002/stem.288>
- Huber, L. C., Ulrich, S., Leuenberger, C., Gassmann, M., Vogel, J., *et al.* (2015). MicroRNA-125a in Pulmonary Hypertension: Regulator of a Proliferative Phenotype of Endothelial Cells. *Experimental Biology and Medicine*, *240*, 1580–1589. <https://doi.org/10.1177/1535370215579018>
- Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., *et al.* (2022). 2022 ESC/ ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension Developed by the Task Force for the Diagnosis and Treatment of (ESC) and the European Respiratory Society (ERS). *European Heart Journal*, *00*, 1–114.
- Humbert, M., McLaughlin, V. V., Badesch, D. B., Ghofran, H. A., Gibbs, J. S. R., *et al.* (2025). Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. *N Engl J Med*, *392*(20), 1987–2000. <https://doi.org/10.1056/NEJMoa2415160>
- Humbert, M., Sitbon, O., & Simonneau, G. (2004). Treatment of Pulmonary Arterial Hypertension. *The New England Journal of Medicine*, *351*, 1425–1436. <https://doi.org/10.1055/s-0037-1607208>

- Huston, J. H., Maron, B. A., French, J., Huang, S., Thayer, T., *et al.* (2019). Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. *JAMA Cardiology*, *37203*, E1–E10. <https://doi.org/10.1001/jamacardio.2019.3345>
- Jilwan, F. N., Escourrou, P., Garcia, G., Jaïs, X., Humbert, M., *et al.* (2013). High Occurrence of Hypoxemic Sleep Respiratory Disorders in Precapillary Pulmonary Hypertension and Mechanisms. *Chest*, *143*(1), 47–55. <https://doi.org/10.1378/chest.11-3124>
- Kassan, M., Vikram, A., Li, Q., Kim, Y., Kumar, S., *et al.* (2017). MicroRNA-204 Promotes Vascular Endoplasmic Reticulum Stress and Endothelial Dysfunction by Targeting Sirtuin1. *Scientific Reports*, 1–11. <https://doi.org/10.1038/s41598-017-06721-y>
- Kim, E. K., & Choi, E. J. (2010). Pathological Roles of MAPK Signaling Pathways in Human Diseases. *Biochimica et Biophysica Acta*, *1802*(4), 396–405. <https://doi.org/10.1016/j.bbadis.2009.12.009>
- Kim, J. D., Lee, A., Choi, J., Park, Y., Kang, H., *et al.* (2015). Epigenetic Modulation as a Therapeutic Approach for Pulmonary Arterial Hypertension. *Experimental & Molecular Medicine*, *47*, 1–11. <https://doi.org/10.1038/emm.2015.45>
- Kok, M. G. M., Ronde, M. W. J. De, Moerland, P. D., Ruijter, J. M., Creemers, E. E., *et al.* (2018). Small Sample Sizes in High-Throughput miRNA Screens : A Common Pitfall for the Identification of miRNA Biomarkers. *Biomolecular Detection and Quantification*, *15*, 1–5. <https://doi.org/10.1016/j.bdq.2017.11.002>
- Kolte, D., Lakshmanan, S., Jankowich, M. D., Brittain, E. L., Maron, B. A., *et al.* (2018). Mild Pulmonary Hypertension Is Associated With Increased Mortality : A Systematic Review and Meta-Analysis. *J Am Heart Assoc*, *7*, 1–13. <https://doi.org/10.1161/JAHA.118.009729>
- Kozlik-Feldmann, R., Hansmann, G., Bonnet, D., Schranz, D., Aplitz, C., *et al.* (2016). Pulmonary Hypertension in Children with Congenital Heart Disease (PAH-CHD, PPHVD-CHD). Expert Consensus Statement on the Diagnosis

- and Treatment of Paediatric Pulmonary Hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by . *Heart (British Cardiac Society)*, *102*, ii42–ii48. <https://doi.org/10.1136/heartjnl-2015-308378>
- Krol, J., Loedige, I., & Filipowicz, W. (2010). The Wdespread Regulation of MicroRNA Biogenesis, Function and Decay. *Nature Reviews Genetics*, *11*(9), 597–610. <https://doi.org/10.1038/nrg2843>
- Kuehbacher, A., Urbich, C., Zeiher, A. M., & Dimmeler, S. (2007). Role of Dicer and Drosha for Endothelial MicroRNA Expression and Angiogenesis. *Circulation Research*, *101*, 59–68. <https://doi.org/10.1161/CIRCRESAHA.107.153916>
- Kurakula, K., Smolders, F. E. D., Tura-ceide, O., Jukema, J. W., Quax, P. H. A., *et al.* (2021). Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence ? *Biomedicines*, *9*(57), 1–23.
- Lang, R. M., Badano, L. P., Victor, M. A., Afilalo, J., Armstrong, A., *et al.* (2015). Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography*, *28*(1), 1-39.e14. <https://doi.org/10.1016/j.echo.2014.10.003>
- Lewis, R. A., Durrington, C., Condliffe, R., & Kiely, D. G. (2020). BNP/NT-probnp in Pulmonary Arterial Hypertension: Time for point-of-care testing? *European Respiratory Review*, *29*(156). <https://doi.org/10.1183/16000617.0009-2020>
- Li, C., Zhang, Z., Xu, Q., & Shi, R. (2020). Comprehensive Analyses of miRNA-mRNA Network and Potential Drugs in Idiopathic Pulmonary Arterial Hypertension. *BioMed Research International*, 1–10.
- Li, X., Xiang, D., Shu, Y., Hu, K., Zhang, Y., *et al.* (2019). MicroRNA-204 as an Indicator of Severity of Pulmonary Hypertension in Children with Congenital Heart Disease Complicated with Pulmonary Hypertension. *Medical Science Monitor*, *25*, 10173–10179. <https://doi.org/10.12659/MSM.917662>

- Li, Y., Wang, D., Li, X., Shao, Y., He, Y., *et al.* (2019). MiR-199a-5p Suppresses Non-Small Cell Lung Cancer via Targeting MAP3K11. *Journal of Cancer*, *10*(11), 2472–2479. <https://doi.org/10.7150/jca.29426>
- Lin, Z. B., Ci, H. B., Li, Y., Cheng, T. P., Liu, D. H., *et al.* (2017). Endothelial Microparticles are Increased in Congenital Heart Diseases and Contribute to Endothelial Dysfunction. *Journal of Translational Medicine*, *15*(4), 1–12. <https://doi.org/10.1186/s12967-016-1087-2>
- Liu, Y., Liu, R., Yang, F., Cheng, R., Chen, X., *et al.* (2017). miR-19a Promotes Colorectal Cancer Proliferation and Migration by Targeting TIA1. *Molecular Cancer*, *16*(1), 1–17. <https://doi.org/10.1186/s12943-017-0625-8>
- Lopes, A. A., Maeda, N. Y. M., Goncalves, R. C., & Bydlowski, S. P. (2000). Endothelial Cell Dysfunction Correlates Differentially with Survival in Primary and Secondary Pulmonary Hypertension. *American Heart Journal*, *139*, 618–623. <https://doi.org/10.1067/mhj.2000.103227>
- Lu, Z., Li, S., Zhao, S., & Fa, X. (2016). Upregulated miR-17 Regulates Hypoxia-mediated Human Pulmonary Artery Smooth Muscle Cell Proliferation and Apoptosis by Targeting Mitofusin 2. *Medical Science Monitor*, *22*, 3301–3308. <https://doi.org/10.12659/MSM.900487>
- Ma, K., Zhao, Q., Chen, W., Zhang, H., Li, S., *et al.* (2015). Human Lung microRNA Profiling in Pulmonary Arterial Hypertension Secondary to Congenital Heart Defect. *Pediatric Pulmonology*, 1–10. <https://doi.org/10.1002/ppul.23181>
- Mandalenakis, Z., Giang, K. W., Eriksson, P., Liden, H., Synnergren, M., *et al.* (2020). Survival in children with congenital heart disease: Have we reached a peak at 97%? *Journal of the American Heart Association*, *9*(22). <https://doi.org/10.1161/JAHA.120.017704>
- Manes, A., Palazzini, M., Leci, E., Reggiani, M. L. B., Branzi, A., *et al.* (2014). Current Era Survival of Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease : a Comparison between Clinical Subgroups. *European Heart Journal*, *35*, 716–724. <https://doi.org/10.1093/eurheartj/ehj072>

- Marshall, X. J. D., Bazan, I., Zhang, Y., Fares, W. H., & Lee, P. J. (2018). Mitochondrial Dysfunction and Pulmonary Hypertension: Cause, Effect, or Both. *Am J Physiol Lung Cell Mol Physiol*, *314*, 782–796. <https://doi.org/10.1152/ajplung.00331.2017>
- Meng, S., Cao, J., Zhang, X., Fan, Y., Fang, L., *et al.* (2013). Downregulation of MicroRNA-130a Contributes to Endothelial Progenitor Cell Dysfunction in Diabetic Patients via Its Target Runx3. *Plos One*, 1–11.
- Michalski, T. A., Pszczola, J., Lisowska, A., Knapp, M., Sobkowicz, B., *et al.* (2022). ECG in the Clinical and Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension: an Underestimated Value. *Therapeutic Advances in Respiratory Disease*, *16*, 1–12. <https://doi.org/10.1177/17534666221087846>
- O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Frontiers in Endocrinology*, *9*(402), 1–12. <https://doi.org/10.3389/fendo.2018.00402>
- Oka, M., Homma, N., Taraseviciene-Stewart, L., Morris, K. G., Kraskauskas, D., *et al.* (2007). Rho kinase-Mediated Vasoconstriction is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats. *Circulation Research*, *100*(6), 923–929. <https://doi.org/10.1161/01.RES.0000261658.12024.18>
- Olsson, K. M., Nickel, N. P., Tongers, J., & Hoeper, M. M. (2013). Atrial Flutter and Fibrillation in Patients with Pulmonary Hypertension. *International Journal of Cardiology*, *167*, 2300–2305. <https://doi.org/10.1016/j.ijcard.2012.06.024>
- Peacock, A. J., Murphy, N. F., McMurray, J. J., Caballero, L., & Stewart, S. (2007). An Epidemiological Study of Pulmonary Arterial Hypertension. *Eur Respir J*, *30*, 104–109.
- Popelová, J. R., Tomková, M., Tomek, J., & Živná, R. (2022). Long-Term Survival of Adult Patients with Atrial Septal Defect with Regards to Defect Closure and Pulmonary Hypertension. *Frontiers in Cardiovascular Medicine*, *9*, 1–8. <https://doi.org/10.3389/fcvm.2022.867012>

- Qiu, X., Lin, J., Liang, B., Chen, Y., Liu, G., *et al.* (2021). Identification of Hub Genes and MicroRNAs Associated with Idiopathic Pulmonary Arterial Hypertension by Integrated Bioinformatics Analyses. *Frontiers in Genetics*, 12(April), 1–11. <https://doi.org/10.3389/fgene.2021.636934>
- Rhodes, C., Wharton, J., Boon, R. A., Roexe, T., Tsang, H., *et al.* (2013). Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. *Am J Respir Crit Care Med*, 187, 294–302.
- Ronde, M. W. J. De, Ruijter, J. M., Moerland, P. D., Creemers, E. E., & Pinto-Sietsma, S.-J. (2018). Review Study Design and qPCR Data Analysis Guidelines for Reliable Circulating miRNA Biomarker Experiments : A Review. *Clinical Chemistry*, 64(9), 1308–1318. <https://doi.org/10.1373/clinchem.2017.285288>
- Rosenzweig, E. B., Abman, S. H., Adatia, I., Beghetti, M., Bonnet, D., *et al.* (2019). Paediatric Pulmonary Arterial Hypertension: Updates on Definition, Classification, Diagnostics and Management. *Eur Respir J*, 53(1801916), 1–18. <https://doi.org/10.1183/13993003.01916-2018>
- Ru, Y., Kechris, K. J., Tabakoff, B., Hoffman, P., Radcliffe, R. A., *et al.* (2014). The multiMiR R Package and Database: Integration of microRNA–Target Interactions Along with Their Disease and Drug Associations. *Nucleic Acids Research*, 42(17), e133–e133. <https://doi.org/10.1093/nar/gku631>
- Saito, K., Kondo, E., & Matsushita, M. (2011). MicroRNA 130 Family Regulates the Hypoxia Response Signal Through the P-body Protein DDX6. *Nucleic Acids Research*, 39(14), 6086–6099. <https://doi.org/10.1093/nar/gkr194>
- Santos-Ferreira, C. A., Abreu, M. T., Marques, C. I., Gonçalves, L. M., Baptista, R., *et al.* (2020). Micro-RNA Analysis in Pulmonary Arterial Hypertension. *J Am Coll Cardiol Basic Trans Science*, 5(11), 1149–1162. <https://doi.org/10.1016/j.jacbts.2020.07.008>
- Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., & Grimminger, F. (2011). Mechanisms of Disease: Pulmonary Arterial Hypertension. *Nature Reviews Cardiology*, 8(8), 443–455. <https://doi.org/10.1038/nrcardio.2011.87>

- Schlosser, K., White, R. J., & Stewart, D. J. (2013). miR-26a linked to pulmonary hypertension by global assessment of circulating extracellular microRNAs. *Am J Respir Crit Care Med*, *188*, 1472–1475.
- Schwartz, S. S., Madsen, N., Laursen, H. B., Hirsch, R., & Olsen, M. S. (2018). Incidence and Mortality of Adults with Pulmonary Hypertension and Congenital Heart Disease. *The American Journal of Cardiology*, 1–24. <https://doi.org/10.1016/j.amjcard.2018.02.051>
- Serra-Juhé, C., Cuscó, I., Homs, A., Flores, R., Torán, N., *et al.* (2015). DNA Methylation Abnormalities in Congenital Heart Disease. *Epigenetics*, *10*(2), 167–177. <https://doi.org/10.1080/15592294.2014.998536>
- Shen, Y., Wan, C., Tian, P., Wu, Y., Li, X., *et al.* (2014). CT-Base Pulmonary Artery Measurement in the Detection of Pulmonary Hypertension. *Medicine*, *93*(27), 1–9. <https://doi.org/10.1097/MD.0000000000000256>
- Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., *et al.* (2013). Updated Clinical Classification of Pulmonary Hypertension. *Journal of the American College of Cardiology*, *62*(25 SUPPL.), D34-41. <https://doi.org/10.1016/j.jacc.2013.10.029>
- Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., *et al.* (2019). Haemodynamic Definitions and Updated Clinical Classification of Pulmonary Hypertension. *Eur Respir J*, *53*, 1801913. <https://doi.org/10.1183/13993003.01913-2018>
- Thomas, C. A., Anderson, R. J., Condon, D. F., & Perez, V. A. de J. (2020). Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium. *Pulm Ther*, *6*, 9–22. <https://doi.org/https://doi.org/10.1007/s41030-019-00105-5>
- Trip, P., Nossent, E. J., De Man, F. S., Van Den Berk, I. A. H., Boonstra, A., *et al.* (2013). Severely Reduced Diffusion Capacity in Idiopathic Pulmonary Arterial Hypertension: Patient Characteristics and Treatment Responses. *European Respiratory Journal*, *42*(6), 1575–1585. <https://doi.org/10.1183/09031936.00184412>

- Vaillancourt, M., Ruffenach, G., Meloche, J., & Bonnet, S. (2015). Adaptation and Remodelling of the Pulmonary Circulation in Pulmonary Hypertension. *Canadian Journal of Cardiology*, 31(4), 407–415. <https://doi.org/10.1016/j.cjca.2014.10.023>
- Ventetuolo, C. E., Moutchia, J., Baird, G. L., Appleby, D. H., McClelland, R. L., *et al.* (2023). Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials. *Annals of the American Thoracic Society*, 20(1), 58–66. <https://doi.org/10.1513/AnnalsATS.202203-207OC>
- Wang, Y., Chen, S., Gao, Y., & Zhang, S. (2017). Serum MicroRNA-27b as a Screening Biomarker. *Texas Heart Institute Journal*, 44(6), 385–389.
- Warnier, M., Roudbaraki, M., Derouiche, S., Delcourt, P., Bokhobza, A., *et al.* (2015). CACNA2D2 Promotes Tumorigenesis by Stimulating Cell Proliferation and Angiogenesis. *Oncogene*, 34(42), 5383–5394. <https://doi.org/10.1038/onc.2014.467>
- Wolf, D., Tseng, N., Seedorf, G., Roe, G., Abman, S. H., *et al.* (2014). Endothelin-1 Decreases Endothelial PPAR γ Signaling and Impairs Angiogenesis After Chronic Intrauterine Pulmonary Hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, 306(4), 2014. <https://doi.org/10.1152/ajplung.00277.2013>
- Woodcock, C.-S. C., & Chan, S. Y. (2019). The Search for Disease-Modifying Therapies in Pulmonary Hypertension. *J Cardiovasc Pharmacol Ther*, 24(4), 334–354. <https://doi.org/10.1177/1074248419829172>
- Wu, W. H., Hu, C. P., Chen, X. P., Zhang, W. F., Li, X. W., *et al.* (2011). MicroRNA-130a Mediates Proliferation of Vascular Smooth Muscle Cells in Hypertension. *American Journal of Hypertension*, 24(10), 1087–1093. <https://doi.org/10.1038/ajh.2011.116>
- Xu, J., Linneman, J., Zhong, Y., Yin, H., Xia, Q., *et al.* (2022). MicroRNAs in Pulmonary Hypertension , from Pathogenesis to Diagnosis and Treatment. *Biomolecules*, 1–16.
- Yamakuchi, M. (2012). MicroRNAs in Vascular Biology. *International Journal of Vascular Medicine*, 2012. <https://doi.org/10.1155/2012/794898>

- Yuan, J. X. J., Aldinger, A. M., Juhaszova, M., Wang, J., Conte, J. V., *et al.* (1998). Dysfunctional voltage-gated K⁺ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. *Circulation*, *98*(14), 1400–1406. <https://doi.org/10.1161/01.CIR.98.14.1400>
- Zeder, K., Banfi, C., Steinrisser-Alex, G., Maron, B. A., Humbert, M., *et al.* (2022). Diagnostic, Prognostic and Differential-Diagnostic Relevance of Pulmonary Hemodynamics During Exercise – a Systematic Review. *European Respiratory Journal*. <https://doi.org/10.1183/13993003.03181-2021>
- Zhang, H., Song, M., Guo, J., Ma, J., Qiu, M., & Yang, Z. (2021). The Function of Non-Coding RNAs in Idiopathic Pulmonary Fibrosis. *Open Medicine (Poland)*, *16*(1), 481–490. <https://doi.org/10.1515/med-2021-0231>
- Zhang, H., Wang, D., Li, M., Plecítá-Hlavatá, L., D’Alessandro, A., *et al.* (2017). Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. *Circulation*, *136*(25), 2468–2485. <https://doi.org/10.1161/CIRCULATIONAHA.117.028069>
- Zhang, J., He, Y., Yan, X., Chen, S., He, M., *et al.* (2020). *MicroRNA-483 Amelioration of Experimental Pulmonary Hypertension*. 1–13. <https://doi.org/10.15252/emmm.201911303>
- Zheng, L., Wang, Z., Li, Z., Wang, M., & Wang, W. (2021). MicroRNA-130a Inhibits Proliferation of Vascular Smooth Muscle Cells by Suppressing Autophagy Via ATG2B. *Journal of Cellular and Molecular Medicine*, *25*(June 2020), 3829–3839. <https://doi.org/10.1111/jcmm.16305>
- Zhou, G., Chen, T., & Raj, J. U. (2015). MicroRNAs in pulmonary arterial hypertension. *Am J Respir Cell Mol Biol*, *52*(2), 139–151. <https://doi.org/10.1165/rcmb.2014-0166TR>